- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01048151
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
A PHASE I SAFETY AND TOLERABILITY TRIAL OF RADIOTHERAPY, ANDROGEN DEPRIVATION, AND INTRATUMORAL INJECTIONS OF AdGVEGR.TNF.11D (TNFeradeTM) FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer. New treatments are being combined with radiation therapy in an effort to further improve the cure rates.
This study proposes to combine an experimental drug, TNFerade™ Biologic, (also called AdGVEGR.TNF.11D or "TNFerade") at different dose (amounts) levels in combination with radiation.
TNFerade™ Biologic is a form of gene transfer therapy that when injected into the tumor has shown to increase the effect of radiation therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Histological documented high-risk localized prostate cancer defined by clinical stage >=T3 or Gleason score ≥8.
- Lack of distant metastases (including bone, liver, or extrapelvic lymph node metastases) on standard CT and bone scanning. Patients with suspected or histologically confirmed pelvic lymph node metastases are eligible.
Normal organ function defined by:
- Hgb > 10 mg/dl (may be transfused or on erythropoietin);
- Platelets > 100,000/l;
- Absolute neutrophil count > 1500/l.
- Bilirubin < 1.5 mg/dl.
- AST and ALT < 1.5X upper limit of normal.
- Written signed informed consent.
Exclusion Criteria
- Absolute or relative contraindication to prostate radiotherapy including but not limited to prior pelvic radiotherapy, active infectious or inflammatory colitis, and inability to lay supine for daily radiation treatments.
- Requirement for ongoing antithrombotic treatment with coumadin or one of its derivatives, heparin or one of its derivatives, or thrombin inhibitors. Low dose aspirin for prevention of cardiovascular events is acceptable.
- Active vascular disease defined as a stroke, transient ischemic attack (TIA), myocardial infarction, or any vascular procedure performed for ischemic disease within the last 6 months.
- History of thrombosis (pulmonary embolism (PE) or deep vein thrombosis (DVT)) or known thrombophilia.
- Coagulopathy (INR>1.5, PTT ratio >1.5)
- Major surgery within the last 1 month (excludes minor superficial surgeries, biopsies, or minimally invasive approaches).
- Chemotherapy or experimental medications within 4 weeks of study entry.
- Chronic treatment for greater than 6 months with oral steroids at doses above 10 mg/day prednisolone (or equivalent).
- Clinical evidence of active infection of any type.
- HIV-positive patients receiving combination anti-retroviral therapy.
- Other significant concurrent medical or psychiatric illness that would limit compliance with study.
- Unwilling to use condoms or another barrier method of birth control for at least 8 weeks following the last dose of TNFerade™ Biologic and some form of birth control for at least one year. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single
TNFerade™ Biologic + Radiation
|
AdGVEGR.TNF.11D
Other Names:
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GV-001.012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Prostate Cancer
-
University of CincinnatiNot yet recruitingCancer | Metastatic Cancer | Locally Advanced Solid Tumor | Locally Advanced | Locally Advanced CarcinomaUnited States
-
IpsenActive, not recruitingMetastatic Prostate Cancer | Advanced Prostate Cancer | Locally Advanced Prostate CancerChina
-
Turku University HospitalUniversity of TurkuActive, not recruitingBenign Prostatic Hyperplasia | Locally Advanced Prostate Cancer | Locally Recurrent Prostate Cancer | Localised Prostate CancerFinland
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AV; General Hospital Groeninge; AZ Sint-Blasius DendermondeRecruitingProstate Cancer | Adenocarcinoma of the Prostate | Locally Advanced Prostate Carcinoma | Locally Advanced Prostate AdenocarcinomaBelgium
-
Medical University of ViennaRecruitingLocally Advanced and Metastatic Prostate CancerAustria
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingNeoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine TherapyChina
-
Merck Sharp & Dohme LLCCompletedMetastatic or Locally Advanced Cancer
-
The First Affiliated Hospital of Xiamen UniversityRecruitingOligometastatic Prostate Cancer | Locally Advanced Prostate CancerChina
-
AstraZenecaCompletedLocally Advanced Prostate CancerNorway
-
Ascenta TherapeuticsTerminatedLocally Advanced Esophageal or GE Junction CancerUnited States
Clinical Trials on TNFerade™ Biologic
-
GenVecCompletedHead and Neck Cancer | Head and Neck NeoplasmsUnited States
-
GenVecCompletedHead and Neck Cancer | Head and Neck NeoplasmsUnited States
-
GenVecCompleted
-
GenVecCompleted
-
GenVecCompletedEsophageal CancerUnited States
-
University of CalgaryMedtronicRecruiting
-
DermTechRecruitingAtopic DermatitisUnited States
-
University of Missouri-ColumbiaCompletedKnee Osteoarthritis | Post-traumatic OsteoarthritisUnited States
-
Miromatrix Medical Inc.Completed